IMRX (STOCKS)
Immuneering Corporation Class A Common Stock
$4.810500
-0.239500 (-4.74%)
Prev close: $5.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Benjamin J. Zeskind
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $320.91M
- Employees
- 54
- P/E (TTM)
- -2.78
- P/B (TTM)
- 1.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.38 | $-0.40 | +0.0198 | +4.95% |
|
Jun 2025 (Q2)
|
$-0.40 | $-0.42 | +0.0233 | +5.50% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.54 | +0.1172 | +21.82% |
|
Dec 2024 (Q4)
|
$-0.58 | $-0.47 | -0.1077 | -22.80% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $64.18M |
| Research and Development | $47.65M |
| Other Operating Expenses | $16.53M |
| Operating Income/Loss | -$64.18M |
| Income/Loss From Continuing Operations After Tax | -$62.50M |
| Income/Loss From Continuing Operations Before Tax | -$62.50M |
| Net Income/Loss | -$62.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$62.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$62.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.79 |
| Diluted Earnings Per Share | -$1.79 |
| Basic Average Shares | 37,435,936 |
| Diluted Average Shares | 37,435,936 |
| Assets | $241.06M |
| Current Assets | $229.10M |
| Noncurrent Assets | $11.95M |
| Fixed Assets | $892.55K |
| Other Non-current Assets | $11.06M |
| Liabilities | $13.08M |
| Current Liabilities | $9.55M |
| Accounts Payable | $1.60M |
| Other Current Liabilities | $7.94M |
| Noncurrent Liabilities | $3.53M |
| Equity | $227.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $227.98M |
| Liabilities And Equity | $241.06M |
| Net Cash Flow From Operating Activities | -$50.01M |
| Net Cash Flow From Operating Activities, Continuing | -$50.01M |
| Net Cash Flow From Investing Activities | $5.47M |
| Net Cash Flow From Investing Activities, Continuing | $5.47M |
| Net Cash Flow From Financing Activities | $226.90M |
| Net Cash Flow From Financing Activities, Continuing | $226.90M |
| Net Cash Flow | $182.36M |
| Net Cash Flow, Continuing | $182.36M |
| Comprehensive Income/Loss | -$62.50M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$62.50M |
| Other Comprehensive Income/Loss | -$62.50M |